GABAA receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment

American Journal of Psychiatry

Volumn 159, Issue 1, 2002, Pages 145-147

  Ströhle, Andreas ^a   Romeo, Elena ^b   Di Michele, Flavia ^b   Pasini, Augusto ^b   Yassouridis, Alexander ^b   Holsboer, Florian ^b   Rupprecht, Rainer ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 ALPHA 5 ALPHA TETRAHYDROPROGESTERONE; 3 ALPHA 5 BETA TETRAHYDROPROGESTERONE; 3 BETA 5 ALPHA TETRAHYDROPROGESTERONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; PAROXETINE; PROGESTERONE DERIVATIVE; STEROID; UNCLASSIFIED DRUG; ELTANOLONE;

ALLOSTERISM; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MAJOR DEPRESSION; NERVE CELL; NERVE CELL EXCITABILITY; PANIC; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ADULT; AGORAPHOBIA; BLOOD; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; STEREOISOMERISM;

ADULT; AGORAPHOBIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PAROXETINE; PREGNANOLONE; RECEPTORS, GABA-A; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 0036357699     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.1.145     Document Type: Article

References (10)

1. Paul SM, Purdy RH: Neuroactive steroids. FASEB J 1992; 6:2311-2322
2. Rupprecht R, Holsboer F: Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999; 22:410-416
3. Ströhle A, Romeo E, di Michele F, Pasini A, Holsboer F, Rupprecht R: Panic attacks shift GABAA receptor modulatory neuroactive steroid composition (abstract). Pharmacopsychiatry 2001; 34:203
4. Bandelow B: Assessing the efficacy of treatments for panic disorder and agoraphobia, II: the Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995; 10:73-81
5. Collegium Internationale Psychiatriae Scalarum: Internationale Skalen für Psychiatrie. Weinheim, Germany, Beltz, 1995
6. Romeo E, Ströhle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R: Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998; 155:910-913
7. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95:3239-3244
8. Ströhle A, Pasini A, Romeo E, Hermann B, Spalletta G, di Michele F, Holsboer F, Rupprecht R: Fluoxetine decreases concentrations of 3α,5α-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res 2000; 34:183-186
9. Griffin LD, Mellon SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999; 96:13512-13517
10. Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D: Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47:534-538